^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Non-Hodgkin’s Lymphoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/22/2021
    Excerpt:
    Peripheral T-Cell Lymphomas...SUGGESTED TREATMENT REGIMENS...Other recommended regimens...Alectinib (ALK+ ALCL only)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

    Excerpt:
    ...Confirmed diagnosis of an ALK-positive malignancy using an analytically validated method....
    Trial ID:
    DETERMINE
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2021
    Title:

    ALK Inhibitor Plus Vinblasitine for Refractory/Relapsed Pediatric ALK+ Anaplastic Large Cell Lymphoma: A Prospective, One-Arm, Open-Label Real-World Study

    Published date:
    11/04/2021
    Excerpt:
    To assess the efficacy and safety of ALK inhibitors combined with VBL in pediatric relapsed/refractory (r/r) ALK+ ALCL....ALK inhibitors included crizotinib(CZ), alectinib(AL) and ceritinib(CER)....After 1st cycle of treatments, 62.9%(17/26) achieved comlpele remission(CR) without measurable tumors and ALK gene transcription, no progressed cases.... ALK inhibitors combined with VBL may rapidly induce the tumor remission of r/r ALK+ALCL and the tolerance is good.
    Secondary therapy:
    vinblastine
    DOI:
    10.1182/blood-2021-149402
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Sci
    Title:

    Alectinib for relapsed or refractory ALK-positive anaplastic large cell lymphoma: an open label phase 2 trial

    Published date:
    10/03/2020
    Excerpt:
    Objective responses were documented in eight of 10 patients (80%; 90% CI: 56.2-95.9), with six complete responses....Alectinib showed favorable clinical activity...in patients with ALK-positive ALCL who had progressed on standard chemotherapy.
    DOI:
    10.1111/cas.14671
    Trial ID:
    CART19-BE-01
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Clin Case Rep
    Title:

    Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin

    Published date:
    11/15/2019
    Excerpt:
    After starting alectinib treatment, the patient demonstrated rapid daily improvement. On day 2, she was afebrile, and her pain was markedly decreased…. At 23 months after transplantation, she remains in complete response (CR) and has not required further treatment for refractory ALK‐positive ALCL...this is the first case report of the use of alectinib as bridging therapy to allo‐SCT in a patient with ALK‐positive ALCL refractory to both conventional chemotherapy and BV.
    DOI:
    10.1002/ccr3.2543